GHRP-2 and Ipamorelin are both growth hormone secretagogues that stimulate GH release by activating the ghrelin receptor (GHS-R1a) — but they differ critically in receptor selectivity, co-stimulation of cortisol and prolactin, and their pharmacological specificity profiles. GHRP-2 is a first-generation synthetic hexapeptide with strong GH-releasing activity accompanied by dose-dependent stimulation of cortisol and prolactin. Ipamorelin is a third-generation pentapeptide engineered specifically to maximise GHS-R1a selectivity while minimising off-target pituitary hormone release — a selectivity profile that has made it the primary subject of more recent research protocols seeking to isolate the GH-release mechanism.
This article compares the molecular pharmacology, receptor profiles, published evidence bases, and research design considerations for GHRP-2 and Ipamorelin — covering what distinguishes these two compounds beyond the search-term surface, and what that distinction means for rigorous preclinical research design. For research purposes only. Not for human consumption.
Key Takeaways
- Both compounds are GHS-R1a agonists (ghrelin receptor). They stimulate GH release from the anterior pituitary through the same primary receptor — the key difference is what else they do.
-
GHRP-2 (CAS:
158861-67-7; MW: 817.9 Da; 6 amino acids) stimulates GH release but also causes dose-dependent increases in cortisol (ACTH axis) and prolactin — off-target effects that must be controlled for in research designs. -
Ipamorelin (CAS:
170851-70-4; MW: 711.9 Da; 5 amino acids) was specifically engineered for GHS-R1a selectivity — it produces robust GH release with minimal cortisol or prolactin co-stimulation at equivalent doses in published studies. - GHRP-2 is better suited for research investigating the full GH-axis/corticotroph/lactotroph response; Ipamorelin is better suited for research isolating the GH secretagogue mechanism without endocrine co-activation.
- Both available from Pure Grade Labs: GHRP-2 10mg and Ipamorelin 10mg. HPLC-verified. For research purposes only. Not for human consumption.
Source GHRP-2 and Ipamorelin for Research
HPLC-verified purity. Batch-specific COA. Available individually. Research use only. Not for human consumption.
Browse GH Research Peptides →What Are Growth Hormone Secretagogues?
Growth hormone secretagogues (GHS) are a class of synthetic peptides and non-peptide compounds that stimulate GH release from the anterior pituitary gland by activating the ghrelin receptor (GHS-R1a). Endogenous ghrelin — the 28-amino acid orexigenic peptide primarily produced in the gastric fundus — is the natural ligand for GHS-R1a. Synthetic GHS compounds were originally developed to investigate the ghrelin/GH axis and as pharmacological tools for diagnosing GH deficiency states.
The development of synthetic GHS compounds progressed through three generations: GHRP-6 (first generation, 1980s), GHRP-2 (second generation, 1990s), and Ipamorelin (third generation, late 1990s). Each iteration refined the receptor selectivity profile — aiming to preserve GH-releasing potency while reducing off-target cortisol and prolactin co-stimulation. Both GHRP-2 and Ipamorelin are GHS-R1a agonists; the difference is how selective that agonism is.
GHRP-2: Mechanism and Pharmacological Profile
GHRP-2 (CAS: 158861-67-7; MW: 817.9 Da) is a synthetic hexapeptide that activates GHS-R1a with high affinity. In preclinical and human studies, GHRP-2 is a potent GH secretagogue — producing GH pulses that mirror the amplitude of natural pulsatile GH secretion. However, GHRP-2 also activates CRH-independent ACTH release from corticotrophs, leading to dose-dependent increases in plasma cortisol, and stimulates prolactin release from lactotrophs.
These off-target effects reflect GHRP-2's non-selective engagement with pituitary signalling pathways beyond the GHS-R1a/somatotroph axis. In research terms, this means any study using GHRP-2 as a GH stimulus must account for concurrent cortisol and prolactin changes as potential confounders. For studies where the objective is to model the full acute neuroendocrine response to GHS-R1a activation — including the corticotroph and lactotroph components — GHRP-2 is the more informative research tool.
GHRP-2 synergises strongly with GHRH analogues. The combination of GHRP-2 and a GHRH analogue such as CJC-1295 produces GH pulses substantially larger than either compound alone. This synergy operates through complementary receptor activation: GHRP-2 activates GHS-R1a on somatotrophs, while CJC-1295 activates the GHRH receptor (GHRHR) on the same cells — the two pathways converge on cAMP and intracellular calcium signalling to produce additive GH secretion.
Ipamorelin: Mechanism and Selectivity Profile
Ipamorelin (CAS: 170851-70-4; MW: 711.9 Da) is a third-generation synthetic pentapeptide developed in the late 1990s with the explicit goal of achieving GHS-R1a agonism with minimal cortisol or prolactin co-stimulation.
In published rodent and porcine studies, Ipamorelin demonstrates GH-releasing potency comparable to GHRP-2 (at equivalent molar doses) with significantly lower cortisol and prolactin co-stimulation. The landmark selectivity study by Johansen PB et al. (1999, PMID: 10027241) compared GH, ACTH, and cortisol responses following equimolar doses of GHRP-6, GHRP-2, and Ipamorelin in rats and pigs — finding that Ipamorelin achieved similar GH-pulse amplitude to GHRP-2 while producing minimal ACTH/cortisol elevation. This selectivity profile has driven adoption of Ipamorelin as the preferred GH secretagogue for research designs where GH-specific effects need to be studied in isolation.
Like GHRP-2, Ipamorelin synergises with GHRH analogues. The Ipamorelin + CJC-1295 research combination is one of the most studied GH secretagogue pairings in the published literature, with both compounds operating via mechanistically complementary (GHS-R1a vs GHRHR) but non-redundant receptor pathways.
Research Context
Dr. Sigrid Andersen, an endocrinology researcher, originally designed her GH pulsatility study using GHRP-2 as the GH stimulus. After her research group raised concerns about cortisol co-activation confounding the downstream GH-IGF-1 axis readouts, she switched to Ipamorelin for the primary study arm — running GHRP-2 as a separate comparison arm. The two-arm design produced cleaner mechanistic data: GH response in isolation (Ipamorelin arm) versus the full neuroendocrine response (GHRP-2 arm) compared directly.
GHRP-2 vs Ipamorelin: Pharmacological Comparison
| Property | GHRP-2 | Ipamorelin |
|---|---|---|
| CAS Number | 158861-67-7 |
170851-70-4 |
| Sequence Length | 6 amino acids (hexapeptide) | 5 amino acids (pentapeptide) |
| Molecular Weight | 817.9 Da |
711.9 Da |
| Primary Receptor | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) |
| GH Release Potency | High — potent somatotroph activation | High — comparable to GHRP-2 at equimolar doses |
| Cortisol Co-Stimulation | Significant — dose-dependent ACTH/cortisol elevation | Minimal — selective GHS-R1a agonism (Johansen 1999) |
| Prolactin Co-Stimulation | Moderate — lactotroph co-activation observed | Minimal — selective GHS-R1a agonism minimises lactotroph effect |
| Generation | 2nd generation GHS | 3rd generation GHS |
| GHRH Synergy | Yes — strong synergy with CJC-1295 | Yes — well-established CJC-1295 + Ipamorelin combination |
| Best Suited For | Full neuroendocrine GHS-R1a response modelling; GH + cortisol axis studies | Isolated GH secretion studies; research requiring selective GH pulse without corticotroph confounding |
GHRP-2 and Ipamorelin — Research-Grade Quality
Both compounds HPLC-verified with batch COA. Available for batch-matched comparative research protocols. Not for human consumption.
Browse GH Secretagogue Research Peptides →Research Design Considerations
The choice between GHRP-2 and Ipamorelin in a research protocol is not a quality question — both are valid, well-characterised GHS-R1a agonists. It is a study design question: what is the question being asked, and which compound's pharmacological profile most cleanly answers it?
Choose GHRP-2 when:
The research question involves the full neuroendocrine response to GHS-R1a activation, including the corticotroph (ACTH/cortisol) and lactotroph (prolactin) components. Also appropriate for comparative studies characterising differences between GHS generations, or when historical comparison with the substantial GHRP-2 preclinical and human literature is valuable.
Choose Ipamorelin when:
The research question is specifically about GH pulse dynamics, GH-IGF-1 axis signalling, or downstream effects of GH secretion — and cortisol co-activation would confound the endpoints. Ipamorelin is the preferred tool for studies where the objective is selective GHS-R1a/somatotroph activation without multi-hormone co-activation.
Use both in comparative protocols:
For research characterising GHS generation differences or validating selectivity claims across models, using both GHRP-2 and Ipamorelin in parallel arms provides the pharmacological comparison data necessary to interpret selectivity-driven experimental variables.
Research Context
A research pharmacologist at a UK CRO was asked to select between GHRP-2 and Ipamorelin for a rat model studying the relationship between pulsatile GH secretion and downstream IGF-1 production in muscle. The choice: Ipamorelin — because the cortisol co-activation from GHRP-2 would independently activate glucocorticoid receptors in muscle tissue, confounding the IGF-1/muscle protein synthesis endpoints. The selectivity profile of Ipamorelin allowed the IGF-1 response to be attributed to the GH pulse without the cortisol interference term.
Frequently Asked Questions
References
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–13. PMID: 10027241.
- Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027–35. PMID: 1849136.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–60. PMID: 9167043.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16822960.
- Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137–42. PMID: 11030300.
GHRP-2 and Ipamorelin — Available for Research
Both compounds available individually with HPLC verification and batch COA. Research use only. Not for human consumption.
Browse All Growth Hormone Research Peptides →Disclaimer: This article is for research and informational purposes only. GHRP-2 and Ipamorelin are not approved by the MHRA for human use and are available only as research chemicals. Research-grade compounds from Pure Grade Labs are sold for in vitro laboratory research purposes only and are not intended for human consumption. This content does not constitute medical advice.